Last reviewed · How we verify
NTQ1062 with Fulvestrant
NTQ1062 with Fulvestrant is a Small molecule drug developed by Nanjing Chia-tai Tianqing Pharmaceutical. It is currently in Phase 1 development.
At a glance
| Generic name | NTQ1062 with Fulvestrant |
|---|---|
| Sponsor | Nanjing Chia-tai Tianqing Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer (PHASE3)
- A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NTQ1062 with Fulvestrant CI brief — competitive landscape report
- NTQ1062 with Fulvestrant updates RSS · CI watch RSS
- Nanjing Chia-tai Tianqing Pharmaceutical portfolio CI
Frequently asked questions about NTQ1062 with Fulvestrant
What is NTQ1062 with Fulvestrant?
NTQ1062 with Fulvestrant is a Small molecule drug developed by Nanjing Chia-tai Tianqing Pharmaceutical.
Who makes NTQ1062 with Fulvestrant?
NTQ1062 with Fulvestrant is developed by Nanjing Chia-tai Tianqing Pharmaceutical (see full Nanjing Chia-tai Tianqing Pharmaceutical pipeline at /company/nanjing-chia-tai-tianqing-pharmaceutical).
What development phase is NTQ1062 with Fulvestrant in?
NTQ1062 with Fulvestrant is in Phase 1.